Stay updated on Pembrolizumab Reirradiation in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Reirradiation in Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab Reirradiation in Glioblastoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocations section now lists study sites in Massachusetts, New York, and Pennsylvania, with the revision updated to v3.3.3. Previously, these state-specific locations were not displayed.SummaryDifference0.4%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision: v3.3.2 has been released, replacing v3.2.0. This update appears to be a minor site version change with no observed modifications to the study details, eligibility criteria, or outcome data on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedRemoved the site-wide government funding status notice from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange Detected- The observed changes are limited to minor textual and formatting updates on the study page and do not alter the primary endpoints, interventions, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check91 days agoChange DetectedUpdate includes a government operations notice and new version tag (v3.2.0) while removing the old version tag (v3.1.0).SummaryDifference2%

- Check98 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Reirradiation in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Reirradiation in Glioblastoma Clinical Trial page.